News | April 07, 2022
Indian pharma growth likely to moderate in FY23: ICRA
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
Headwinds related to pricing pressures and rising raw material costs will result in some contraction in margins in Q4 FY22 and FY23
The new reagents will bring the exceptional sensitivity of the company’s liquid format 1-step RT-qPCR reagents to a freeze-dryable format
GE Healthcare and Elekta aim to meet the major need for radiotherapy solutions across both developed and developing markets
Ind-Ra maintains a neutral outlook for healthcare in FY23
Announces pilot project for rapid, remote diagnosis of tuberculosis
Drones will be used in the Gurugram and Mumbai region to transport pathology samples
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The two-day event will showcase achievements and address issues pertaining to the industry
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
It aims to make the state-of-the-art modern and safe surgical care, typically available in super-speciality hospitals of big cities, accessible, affordable, standardized and integrated
Subscribe To Our Newsletter & Stay Updated
